NCT05177211View on ClinicalTrials.gov

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

April 10, 2025

Study Completion Date

April 30, 2026

Conditions
Myeloproliferative NeoplasmChronic Neutrophilic LeukemiaMDS
Interventions
DRUG

Fedratinib Pill

Participants will be given Fedratinib at a dose of 400 mg PO once daily (4-100 mg capsules). Fedratinib can be given at any time during the day, but patients are advised to take the dose at the same approximate time every day.

Trial Locations (3)

33612

Moffitt Cancer Center, Tampa

44195

Cleveland Clinic, Cleveland

48109

University of Michigan Rogel Cancer Center, Ann Arbor

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT05177211 - Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) | Biotech Hunter | Biotech Hunter